Brokerages Set vTv Therapeutics Inc. (NASDAQ:VTVT) Target Price at $55.25

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $55.25.

Several research firms have weighed in on VTVT. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Roth Mkm assumed coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. TD Cowen began coverage on vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, BTIG Research reiterated a “buy” rating and set a $49.00 target price (up from $40.00) on shares of vTv Therapeutics in a report on Tuesday, January 27th.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $39.32 on Tuesday. The firm has a market capitalization of $154.92 million, a price-to-earnings ratio of -11.84 and a beta of 0.50. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The stock’s fifty day moving average is $36.51 and its two-hundred day moving average is $27.86.

Institutional Trading of vTv Therapeutics

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the 4th quarter valued at about $221,000. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth about $731,000. Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its position in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.